SANOFI, SANOFI-AVENTIS U.S., LLC V. WATSON LABS. INC., SANDOZ, INC.
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summaries
Before PROST, WALLACH, and TARANTO. Appeal from the District of Delaware
Summary: (1) A party may not avoid inducement based on “substantial non-infringing uses,” and (2) prosecution history estoppel does not apply to a narrowing amendment in a parent application that was not present in the patent-in-suit.
Sanofi sued Watson and Sandoz for infringement of the ‘167 and ‘800 patents. The district court found that Watson and Sandoz induced infringement of the ‘167 patent based on their proposed drug labels, which contained an indication for reducing the risk of hospitalization in certain conditions. The district court also found Watson and Sandoz infringed the ‘800 patent after rejecting their argument that prosecution history estoppel applied. Watson and Sandoz appealed to the Federal Circuit.
Watson and Sandoz argued they did not induce infringement of the ‘167 patent because their drugs had substantial non-infringing uses that were not forbidden by their labels. The Federal Circuit disagreed. Unlike contributory infringement, inducement does not contain a “substantial non-infringing use” restriction. Because the labels encouraged an infringing use, that was sufficient for inducement even if the drugs could be used in non-infringing ways.
The Federal Circuit also rejected Watson’s and Sandoz’s argument that prosecution history estoppel applied to the ‘800 patent. Sanofi had added a narrowing limitation to the claims of a parent application, but removed it from the application that became the ‘800 patent. The Federal Circuit held that prosecution history estoppel did not apply because Sanofi merely obtained “immediate issuance of a patent containing narrowed claims and postpone[d] to the prosecution of a continuation application further arguments about claims that lack the narrowing limitation.” Thus, the Federal Circuit affirmed.
This case is: SANOFI, SANOFI-AVENTIS U.S., LLC V. WATSON LABS. INC., SANDOZ, INC.
Written By: Adam Powell and Brandon Smith
Editor: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…